Colección SciELO Chile

Departamento Gestión de Conocimiento, Monitoreo y Prospección
Consultas o comentarios: productividad@anid.cl
Búsqueda Publicación
Búsqueda por Tema Título, Abstract y Keywords



Primary Aldosteronism in a Hispanic Cohort: Responses to Mineralocorticoid Receptor Antagonism and Remission in a Case
Indexado
WoS WOS:001448040900001
DOI 10.1093/AJH/HPAF020
Año 2025
Tipo artículo de investigación

Citas Totales

Autores Afiliación Chile

Instituciones Chile

% Participación
Internacional

Autores
Afiliación Extranjera

Instituciones
Extranjeras


Abstract



BACKGROUND Primary aldosteronism (PA) is the main cause of secondary arterial hypertension. In this study, we present the medical treatment of Hispanic patients with PA followed for up to 5 years, highlighting the complete cure with pharmacological treatment in one of our patients.METHODS We studied 32 PA patients, followed every 6 months after starting MRA. A clinical response was the normalization of blood pressure (BP) in the absence of other antihypertensive drugs. The biochemical response was considered with normalization of potassium and renin. Responses to treatment were compared using the defined daily dose (DDD). The effect of MRA was evaluated in vitro. The HAC15 cells were cultured and stimulated with aldosterone and spironolactone for 24-72 h, and the apoptotic cell death was measured.RESULTS At 12 months posttreatment with MRA, 68% of the patients had a total clinical response, and 67% had a total biochemical response. Response to MRA treatment reduced DDD by an average of 74%. Additionally, we observed one PA patient treated with spironolactone after 3 years, he presented a pharmacological cure with normalization of aldosterone and renin without treatment with spironolactone. The in vitro study shows that spironolactone increased early apoptosis by 60% and late apoptosis by 50%.CONCLUSIONS These results suggest the importance of timely diagnosis of PA and specific treatment with MRA, especially in patients with a poor response to treatment. Moreover, remission of PA may occur in some patients after spironolactone treatment due to its suggestive role as an apoptotic agent.

Métricas Externas



PlumX Altmetric Dimensions

Muestra métricas de impacto externas asociadas a la publicación. Para mayor detalle:

Disciplinas de Investigación



WOS
Peripheral Vascular Disease
Peripheral Vascular Diseases
Scopus
Internal Medicine
SciELO
Sin Disciplinas

Muestra la distribución de disciplinas para esta publicación.

Publicaciones WoS (Ediciones: ISSHP, ISTP, AHCI, SSCI, SCI), Scopus, SciELO Chile.

Colaboración Institucional



Muestra la distribución de colaboración, tanto nacional como extranjera, generada en esta publicación.


Autores - Afiliación



Ord. Autor Género Institución - País
1 Tapia-Castillo, Alejandra Mujer Pontificia Universidad Católica de Chile - Chile
Ctr Traslac Endocrinol UC CETREN UC - Chile
Universidad Finis Terrae - Chile
2 Vecchiola, Andrea - Pontificia Universidad Católica de Chile - Chile
Ctr Traslac Endocrinol UC CETREN UC - Chile
3 Quinones, Paola - Pontificia Universidad Católica de Chile - Chile
4 Baudrand, Rene - Pontificia Universidad Católica de Chile - Chile
Ctr Traslac Endocrinol UC CETREN UC - Chile
5 USLAR-NAWRATH, THOMAS Hombre Pontificia Universidad Católica de Chile - Chile
Ctr Traslac Endocrinol UC CETREN UC - Chile
6 Delgado, Jose - Hospital Dr Sotero del Rio - Chile
7 Carvajal, Cristian A. - Pontificia Universidad Católica de Chile - Chile
Ctr Traslac Endocrinol UC CETREN UC - Chile
8 Fardella, Carlos E. - Pontificia Universidad Católica de Chile - Chile
Ctr Traslac Endocrinol UC CETREN UC - Chile

Muestra la afiliación y género (detectado) para los co-autores de la publicación.

Financiamiento



Fuente
CETREN-UC
ICM-ANID
ANID-CONICYT FONDECYT
Anillo-ANID

Muestra la fuente de financiamiento declarada en la publicación.

Agradecimientos



Agradecimiento
This work was supported by the following grants: ANID-CONICYT FONDECYT 1212006, 1190419 and 11251675; ICM-ANID ICN2021_045; ANILLO-ANID ACT210039; SOCHED 2024-06 and CETREN-UC.

Muestra la fuente de financiamiento declarada en la publicación.